First Preclinical Imaging of Erbium-165 for Cancer Treatment
Author Information
Author(s): Saeedi Saghez Behrad, Rodríguez-Rodríguez Cristina, Esquinas Pedro Luis, Merkens Helen, Bénard François, Radchenko Valery
Primary Institution: TRIUMF, University of British Columbia, BC Cancer Research Institute
Hypothesis
Can Erbium-165 be effectively used for SPECT imaging and biodistribution studies in cancer treatment?
Conclusion
The study successfully demonstrated the use of Erbium-165 for preclinical SPECT imaging and its potential as a tool for evaluating targeted radiopharmaceuticals.
Supporting Evidence
- Erbium-165 was produced with high yield and purity using a cyclotron.
- The radioligand [165Er]Er-PSMA-617 showed high stability in serum.
- SPECT imaging demonstrated good tumor uptake in preclinical models.
- Quantitative accuracy of SPECT images was validated against ex vivo biodistribution.
Takeaway
This study shows that a special type of Erbium can help doctors see tumors better using special imaging techniques, which could help treat cancer.
Methodology
The study involved producing Erbium-165, synthesizing radioligands, and conducting SPECT imaging and biodistribution studies in tumor-bearing mice.
Limitations
The study is preclinical and results may not directly translate to human applications.
Participant Demographics
Male NRG mice bearing LNCaP tumors were used for the studies.
Statistical Information
Confidence Interval
95%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website